Pomerantz Law Firm Launches Investigation into Sarepta Therapeutics for Investor Claims

Investor Alert: Pomerantz Law Firm Investigates Sarepta Therapeutics



Pomerantz LLP, a leading law firm known for its expertise in corporate and securities class action litigation, is currently conducting an investigation on behalf of investors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). This inquiry focuses on potential securities fraud or other illicit business practices allegedly engaged in by Sarepta and select company executives.

Recent Developments


On March 18, 2025, Sarepta released a troubling press statement announcing the death of a patient suffering from Duchenne muscular dystrophy after receiving treatment with ELEVIDYS, their drug designed for this condition. According to the report, the patient experienced acute liver failure following the treatment. This news prompted an immediate market reaction, resulting in Sarepta's stock price plunging by $27.81, a decrease of approximately 27.44%, closing at $73.54 on the same day.

In a subsequent development on June 16, 2025, Sarepta reported another case of a patient who succumbed to acute liver failure after using Elevidys. This led the company to halt its ongoing clinical trials and suspend the drug's distribution for patients who are unable to walk. Following this announcement, Sarepta's stock experienced a significant decline, dropping $15.24 or 42.12%, closing at $20.94.

Taking Action


Given these alarming developments, Pomerantz LLP encourages affected investors to reach out for guidance. Danielle Peyton, a member of the firm, can be contacted at Danielle Peyton at [email protected] or by phone at 646-581-9980, extension 7980. Those who believe they have been adversely impacted are urged to consider joining the class action lawsuit.

With over 85 years of experience in class action litigation, Pomerantz has established itself as a formidable entity in pursuing justice for shareholders and standing against corporate misconduct. The firm’s commitment to safeguarding investor rights has resulted in substantial financial recoveries in previous cases of securities fraud and breach of fiduciary duty.

Legal Disclaimer


It’s important to note that prior outcomes achieved by Pomerantz LLP do not guarantee similar results in potential future cases. The firm remains dedicated to the principles laid down by its founder, Abraham L. Pomerantz, who is recognized as a pioneer in class action law. The firm continues to advocate fiercely for victims of corporate malfeasance and securities fraud, holding those responsible accountable for their actions.

For more information, insights, and updates on this investigation, please visit www.pomlaw.com. Investors should stay informed and proactive in protecting their interests amidst these significant developments regarding Sarepta Therapeutics.

Topics Financial Services & Investing)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.